Catalent Inc (CTLT) : Integrated Investment Consultants added new position in Catalent Inc during the most recent quarter end. The investment management firm now holds 6,963 shares of Catalent Inc which is valued at $164,188 , the company said in a statement filed on Oct 14, 2016 with the SEC.Catalent Inc makes up approximately 0.08% of Integrated Investment Consultants’s portfolio.
Other Hedge Funds, Including , Creative Planning boosted its stake in CTLT in the latest quarter, The investment management firm added 26 additional shares and now holds a total of 111 shares of Catalent Inc which is valued at $2,739.Oregon Public Employees Retirement Fund boosted its stake in CTLT in the latest quarter, The investment management firm added 739 additional shares and now holds a total of 37,259 shares of Catalent Inc which is valued at $974,323. Catalent Inc makes up approx 0.02% of Oregon Public Employees Retirement Fund’s portfolio.First Mercantile Trust Co reduced its stake in CTLT by selling 430 shares or 7.8% in the most recent quarter. The Hedge Fund company now holds 5,080 shares of CTLT which is valued at $130,454. Catalent Inc makes up approx 0.02% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in CTLT by selling 27,828 shares or 58.55% in the most recent quarter. The Hedge Fund company now holds 19,698 shares of CTLT which is valued at $509,587.
Catalent Inc closed down -0.15 points or -0.63% at $23.58 with 8,29,900 shares getting traded on Friday. Post opening the session at $23.93, the shares hit an intraday low of $23.42 and an intraday high of $24.07 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Catalent Inc reported $0.52 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Aug 29, 2016. Analyst had a consensus of $0.53. The company had revenue of $532.20 million for the quarter, compared to analysts expectations of $500.46 million. The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.61 EPS.
Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.